anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a new Frizzled-4 polypeptide containing an amino acid sequence having high identity to a sequence over the whole length of a specific amino acid sequence and useful for the treatment diagnosis, etc., of neurological disorder, cancer, osteopathy, cardiovascular disease, apoplexy, etc. SOLUTION: The objective polypeptide is a separated new Frizzled-4 polypeptide containing an amino acid sequence having an identity of at least 98% to the amino acid sequence of the formula over the whole length of the formula. It is useful for the treatment diagnosis, etc., of neurological disorder (e.g. schizophrenia, bipolar/monopolar disorder, Alzheimer's disease and epilepsy), cancer, osteopathy (e.g. osteoporosis-pseudoglioma syndrome), cardiovascular disease, apoplexy, type I Usher's syndrome development disorder, etc. The polypeptide can be produced by standard cloning and screening technique from a DNA library induced from mRNA in human placenta cell by producing a polynucleotide from the library by expressed sequence tag(EST) analysis and expressing the polynucleotide in a host cell.
Currently, in the US, Asacol therapy is indicated in divided doses for the maintenance of remission of ulcerative colitis at 1.6 g/day. A once daily dose is potentially beneficial to patients and physicians alike. This study will answer the following questions about once daily dosing: (1) does efficacy differ between once daily and twice daily dosing, (2) do patients prefer a once daily dosing regimen, and (3) is compliance better? This study will confirm whether there are benefits to once daily dosing beyond increased convenience. In order to understand how the QD regimen compares to BID in a "real life" practice setting, the patient will remain on the total daily dose of Asacol (1.6 g/day to 2.4 g/day) on which they were maintained in remission, but will be assigned to either a QD or BID regimen. This is an investigator-blinded study.
Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
FIELD: medicine.SUBSTANCE: group of inventions includes the intravesical drug delivery device, and the drug to the patient controlled release provision method, relates to the field of medicine, and is intended for the drug release for therapeutic treatment. Intravesical drug delivery device comprises housing, comprising the drug reservoir closed cavity, limited by the first wall structure from the first material and the hydrophilic second wall structure from the second material, and the medicament contained in the drug reservoir cavity. First wall structure is made impermeable to the medicament, and the second wall structure is made permeable to the medicament. First wall structure is the cylindrical tube, and the second wall structure is the end wall, disposed at least on one end of the cylindrical tube, or the first wall structure and the second wall structure are adjacent to each other, and together form the cylindrical tube. First and second materials hardness is selected to make the device susceptible in the patient's bladder. Drug to the patient controlled release provision method consists in the fact, that deploying the drugs delivering device in the patient's body, wherein the said device comprises the drug reservoir closed cavity, limited by the first wall structure from the first material and the hydrophilic second wall structure from the second material, and releasing the drug from the drug reservoir cavity by penetration through the second wall structure.EFFECT: inventions allow the drugs delivery inside the bladder with effective release rates for the certain group of different drugs over the long period of time and pain relief during the device deployment in the bladder cavity.26 cl, 37 dwg
UNLABELLED: Mounting evidence links systemic innate immunity with cancer immune surveillance. In advanced metastatic castration-resistant prostate cancer (mCRPC), Black patients have been found to have increased inflammatory markers and longer survival after sipuleucel-T (sip-T) therapy, an FDA-approved, autologous cell therapy. We hypothesized these differences may be explained by previously reported ancestral differences in pattern recognition receptor signaling, which broadly governs innate inflammation to control adaptive immune cell activation, chemotaxis, and functionality. We discovered that peripheral blood mononuclear cell IFN-β responses to Toll-like receptor 1/2 (TLR1/2), a sensor of bacterial and gut microbiome constituents, associated with significantly longer survival after sip-T therapy in two separate cohorts of men with mCRPC (discovery cohort: n = 106, HR = 0.12; P = 0.019; validation cohort: n = 28, HR < 0.01; P = 0.047). Higher IFN-β induction after TLR1/2 stimulation was associated with lower HRs than biomarkers of vaccine potency and other prognostic factors in mCRPC. TLR1/2-dependent cytokine induction was stronger in Black individuals (1.2-fold higher for IFN-β; P = 0.04) but was associated with survival independently of race or numbers of vaccine-induced tumor antigen-specific T cells. IFN-β responses to TLR1/2 signaling correlated with increased numbers of IFN-γ producing T cells after broad, tumor antigen-independent stimulation. Thus, peripheral innate immunity differs by race, may predict survival after sip-T, and associates with peripheral T-cell functionality in men with mCRPC.
SIGNIFICANCE: The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies and to uncover routes to sensitize patients with cancer to immunotherapy. Our work links functional peripheral immune responses with race and survival after cellular immunotherapy in men with mCRPC.
Multiple stroke severity scales have been coined in order to examine patients suspected of stroke in a prehospital setting in order to identify and transfer patients eligible for thrombectomy directly to a comprehensive stroke centre (CSC). However, performance and feasibility vary greatly in different validation studies suggesting that those outcomes are greatly dependent on other factors i.e. acceptance amongst stakeholders, implementation process, patient segment etc. Some recent studies have shown promising results using telemedicine i.e. video solutions between emergency medical services (EMS) personnel and on-call neurologist in examining patients suspected of stroke in the prehospital phase. The investigators will perform this trial to examine whether a cluster randomised trial with video call assisted assessment of patients suspected of stroke in a prehospital setting is an appropriate trial design and feasible with regard to recruitment and retention, acceptability among stakeholders (EMS and neurologists) as well as patients and lastly with regard to stakeholders' adherence to protocol.
The crisis response planning (CRP) session will last between 30 minutes to 1-hour. It will occur face-to-face with a trained study therapist. The CRP session involves the following standard suicide intervention strategies: supportive listening, provision of crisis resources, and referral to a mental health professional (if not already established). The CRP active component involves a collaborative process in which the therapist invites the patient to share the events, symptoms, and contextual factors leading up to and surrounding the participant's suicidal crisis. Next, the patient and therapist identify the patient's personal warning signs for an emotional crisis, self-management coping skills, patient's reasons for living, and sources of social support. These components are written, by the patient, on an index card. The index card serves as a concrete reference for patients in the real-world.
It was proposed that emotional eating is a critical factor to address early in a behavioral obesity treatment for women to improve their long-term weight-loss, which has been problematic. Poor body image/body satisfaction is a likely predictor of emotional eating. Possible social cognitive theory-based mediators of the body satisfaction-emotional eating relationship having treatment implications include disturbed mood and self-efficacy for controlled eating. Women with obesity volunteered for a community-based weight loss program. After confirming salience of disturbed mood and self-efficacy for controlling one's eating as mediators of the body satisfaction-emotional eating relationship at baseline, a 3-month protocol emphasizing exercise and targeting those mediators through a focus on self-regulation was developed and administered to the treatment group (n = 86). The control group (n = 51) received matched time in typical, educationally based weight-loss processes. Improvements in body satisfaction, emotional eating, disturbed mood, and self-efficacy for controlled eating from baseline-month 3 were each significantly greater in the treatment group. Further analysis of the treatment group found that changes in disturbed mood and self-efficacy completely mediated the body satisfaction change-emotional eating change relationship and neither age nor race (White/Black) were significant moderators. Improvement in emotional eating from baseline-month 3 significantly predicted lost weight over both 3 months and with changes incorporating a 6-month follow up. Findings confirmed the importance of addressing the relationship between body satisfaction and emotional eating over the critical initial months of a behavioral obesity treatment for women through targeting improvements in mood and controlled eating-related self-efficacy.
The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae with one or more genetic modifications. The present invention also relates to the mutant components, i.e., nucleic acids and proteins, of these mutant mammalian MPVs. These mutant mMPV can be attenuated. These mutant mMPVs can encode non-native sequences. The invention further relates to vaccine formulations comprising the mMPV, including recombinant and chimeric forms of said viruses. The vaccine preparations of the invention encompass multivalent vaccines, including bivalent and trivalent vaccine preparations. In addition, the invention relates to chimeric viral RNA polymerase complex and assays using these chimeric RNA polymerase complexes. The chimeric RNA polymerase complexes of the invention are composed of different RNA polymerase components from different viruses of the family of paramyxoviridae.
Problem to be solved is to provide a compound or a pharmaceutical composition thereof having excellent syk (Spleen Tyrosine Kinase) inhibitory activity. Solution is to provide a nicotinamide derivative or salt thereof and a pharmaceutical composition for Syk-related disease containing the nicotinamide derivative or salt thereof, wherein the nicotinamide derivative is represented by the formula (I) (In the formula, R1 represents a halogen atom. R2 respectively represents a substituted or unsubstituted C1-12 alkyl, a C2-12 alkenyl, a C2-12 alkynyl, a C3-8 cycloalkyl, an aryl, a aryl C1-6 alkyl or a heterocyclic group. R3 represents a substituted or unsubstituted aryl or heterocyclic group. R4 and R5 represents hydrogen atom, ect. R2 and R4 may form a substituted or unsubstituted cycloamine together with nitrogen atom bonding with R2 and R4)?
Change in contraceptive effectiveness associated with coadministration of other products:

a. Anti-infective agents and anticonvulsants. Contraceptive effectiveness may be reduced when hormonal contraceptives are coadministered with antibiotics, anticonvulsants, and other drugs that increase the metabolism of contraceptive steroids. This could result in unintended pregnancy or breakthrough bleeding. Examples include rifampin, barbiturates, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, and griseofulvin.

b. Anti-HIV protease inhibitors. Several of the anti-HIV protease inhibitors have been studied with coadministration of oral contraceptives; significant changes (increase and decrease) in the plasma levels of the estrogen and progestin have been noted in some cases. The safety and efficacy of OC products may be affected with the coadministration of anti-HIV protease inhibitors. Health care providers should refer to the label of the individual anti-HIV protease inhibitors for further drug-drug interaction information.

c. Herbal products. Herbal products containing St. John's Wort (hypericum perforatum) may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and may reduce the effectiveness of contraceptive steroids. This may also result in breakthrough bleeding.
Subjects who meet criteria for study entry come to UCSD where consenting and a comprehensive screening and diagnostic assessment including a Mini-International Neuropsychiatric Interview are conducted. After initial screening, subjects return twice, approximately 7 days apart, for biomarker assessment after challenge with placebo (PBO) (Test 1) or amphetamine 5 mg po (AMPH) (Test 2). Subjects then enter the "treatment phase", completing up to 30 one-hour targeted cognitive training (TCT) sessions. Subjects are randomized to one of 2 groups: "AMPH Group" receive AMPH (5 mg po) 1h before each TCT session; "PBO Group" receive PBO dosed identically to AMPH. Pill identity (AMPH vs. PBO) is blind to subjects and staff.

TCT sessions are scheduled approximately 3 times each week for 10 weeks. TCT consists of 7 computerized exercises delivered on standardized laptops and headphones. Collectively, these exercises target learning mechanisms involving auditory perception and processing speed (Sound Sweeps, Fine Tuning) and auditory memory (Syllable Stacks, Memory Grid, To-Do List Training, Rhythm Recall, Hear-Hear). Training is structured into blocks that deliver stimulus sets with varying temporal and psychophysical parameters to allow continuous learning and improvement. Blocks consist of 10-35 adaptive trials where the subject's progression depends on their performance. Exercises apply an n-up/m-down algorithm to responses to estimate psychophysical thresholds while ensuring that participants remain engaged and challenged at an appropriate level (\~80% accuracy) as their abilities improve.

Clinical and functional outcome measures are acquired at "baseline", and 1-2 days after completion of 10, 20 and 30 TCT sessions and 12 weeks post-training. Urine toxicology screens and Columbia Suicide Severity Rating Scales are performed at least weekly, prior to a TCT session. A treatment satisfaction scale (100 mm line) rates expectations at the start of the study and actual experience of treatment in three areas: "satisfaction", "hard work" and "worthwhile." Subjects from both groups return to UCSD 12 weeks after the TCT has ended, and outcome measures are reassessed to test the "durability" of benefits.
Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. MAb has a glycan structure generally of the 'two-antennae' type, with short chains, low level of silylation of mannose and GlcNAc at the non-intercalated terminal points of attachment, low level of fucosylation and non-zero level of intermediate GlcNAc. ACTIVITY : Cytostatic; Hematological; Antibacterial; Parasiticide. No details of tests for these activities are given. MECHANISM OF ACTION : Immunotherapy; inducing stimulation of cytokine secretion and thus antibody-dependent cellular cytotoxicity.
BACKGROUND: Atrial fibrillation and flutter (AFF) are the most common cardiac arrhythmias globally, contributing to substantial morbidity and mortality. The Middle East and North Africa (MENA) region face unique challenges in managing cardiovascular diseases, including AFF, due to diverse sociodemographic factors and healthcare infrastructure variability. This study aims to comprehensively evaluate the burden of AFF in MENA from 1990 to 2019.
METHODS: Data were obtained from the Global Burden of Diseases Study 2019, a comprehensive source incorporating diverse data inputs. The study collected global, regional, and national Age-Standardized Incidence Rate (ASIR), Age-Standardized Mortality Rate (ASMR), and Age-Standardized Disability-Adjusted Rate (ASDR), Mortality across sex, age groups, and years. LOESS regression was employed to determine the relationship between age-standardized rates attributed to AFF and Socio-Demographic Index (SDI).
RESULTS: The study found minimal change in ASIR of AFF in MENA from 1990 to 2019, with a slight increase observed in ASMR and ASDR during the same period. Notably, AFF burden was consistently higher in females compared to males, with age showing a direct positive relationship with AFF burden. Iraq, Iran, and Turkey exhibited the highest ASIR, while Qatar, Bahrain, and Oman had the highest ASMR and ASDR in 2019. Conversely, Kuwait, Libya, and Turkey displayed the lowest ASMR and ASDR rates.
CONCLUSION: This study underscores the persistent burden of AFF in MENA and identifies significant disparities across countries. High systolic blood pressure emerged as a prominent risk factor for mortality in AFF patients. Findings provide crucial insights for policy-making efforts, resource allocation, and intervention strategies aimed at reducing the burden of cardiovascular diseases in the MENA region.
A mixed extract of black garlic, Melonis Pedicellus(Cucumis melo var. makuwa MAKINO) and Allii Radix(Allium fistulosum L.) is provided to suppress hyaluronidase activity and lipoxygenase activity and remove free radical. A mixed extract contains a black garlic, Melonis Pedicellus(Cucumis melo var. makuwa MAKINO) and Allii Radix(Allium fistulosum L.) in a weight ratio of 1: 0.1~5: 0.1~5 . The mixed extract is isolated using water, methanol, ethanol, propanol, ethylacetate or their mixed solvent. A cosmetic composition comprises 0.001~5 weight% of mixed extract. The cosmetic composition is used in the form of skin softener, nutrition lotion, nutrition cream, massage cream, essence, and pack.
This is a phase 1 single-center, randomized (the study drug is assigned by chance), parallel group (each group of participants will be treated at the same time), placebo-controlled (study in which the experimental treatment or procedure is compared to a pretend treatment with no drug in it to test if the drug has a real effect), and double-blind (neither physician nor participant knows the treatment that the participant receives) study. Participants will be randomized in to 3 groups and will receive study vaccines or placebo. Group 1 will have 4 vaccination time points during 48 weeks, Groups 2 and 3 will have 3 vaccination time points during 24 weeks. The study comprises a Screening Period (up to 4 weeks), a Vaccination Period (maximum 48 weeks), and a Follow-up Period (up to 72 weeks). Participants' safety will be monitored throughout the study. An optional Long-term Extension (LTE) phase (approximately 1 year after Week 72) will be performed for participants randomized to receive study vaccine, who have received all planned vaccinations and are negative for HIV infection at Week 72. The duration of the participation will be approximately 124 weeks for participants participating to the optional LTE phase.
Patients receive radium-223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone scan, and CT or MRI throughout the study.
Gut microbiota may be involved in the presence of irritable bowel syndrome (IBS)-like symptomatology in ulcerative colitis (UC) patients in remission. Bread is an important source of dietary fiber, and a potential prebiotic. To assess the effect of a bread baked using traditional elaboration, in comparison with using modern elaboration procedures, in changing the gut microbiota and relieving IBS-like symptoms in patients with quiescent ulcerative colitis. Thirty-one UC patients in remission with IBS-like symptoms were randomly assigned to a dietary intervention with 200 g/d of either treatment or control bread for 8 weeks. Clinical symptomatology was tested using questionnaires and inflammatory parameters. Changes in fecal microbiota composition were assessed by high-throughput sequencing of the 16S rRNA gene. A decrease in IBS-like symptomatology was observed after both the treatment and control bread interventions as reductions in IBS-Symptom Severity Score values (p-value < 0.001) and presence of abdominal pain (p-value < 0.001). The treatment bread suggestively reduced the Firmicutes/Bacteroidetes ratio (p-value = 0.058). In addition, the Firmicutes/Bacteroidetes ratio seemed to be associated with improving IBS-like symptoms as suggested by a slight decrease in patient without abdominal pain (p-value = 0.059). No statistically significant differential abundances were found at any taxonomic level. The intake of a bread baked using traditional elaboration decreased the Firmicutes/Bacteroidetes ratio, which seemed to be associated with improving IBS-like symptoms in quiescent ulcerative colitis patients. These findings suggest that the traditional bread elaboration has a potential prebiotic effect improving gut health (ClinicalTrials.gov ID number of study: NCT05656391).
Participants will receive belzutifan 160 mg orally twice daily (BID). Treatment will continue until progressive disease or discontinuation.
All participants will receive 36 weeks of sotatercept therapy. Sotatercept is administered as a subcutaneous injection once every 3 weeks.
The invention relates to a formula and preparation method of a traditional Chinese medicine for treating kidney/bladder channel tissue disease. The traditional Chinese medicine is prepared from 3g of notopterygium root, 3g of phellodendron bark, 2g of Dittany Bark, 2g of creat, 2g of versioolor swallowwort root, 3g of heracleum hemsleyanum michaux, 2g of Trachelospermum jasminoides, 2g of homalomena rhizoma, 2g of amomum fruit, 3g of Polyporus umbellatus, 3g of Dioscorea tokoro Makino, 2g of motherwort, 3g of radix linderae, 2g of Endothelium Corneum Gigeriae Galli, 2g of cogongrass rhizome, 2g of radix achyranthis bidentatae, 2g of semolina seed, 2g of polygala root, 2g of lumbricus, 2g of ginseng, 2g of ursine seal's penis and teste, 2g of placenta hominis, 2g of Chinese chestnut and 1g of Mullein Mightbrier Leaf. The invention selects the following acupoints: Zutonggu, Shugu, Yongquan, Feiyang, Fuliu, Weizhong, Zhishi, Yishe, Henggu, Fengmen, Shenfeng, Yufu, Tianzhu, Wuchu and Meichong. The invention adopts the following auxiliary instruments: a barrel for containing discharged foreign matters, a barrel for introducing medicines, an auxiliary barrel, an ozone generator, an ultrasonic generator for discharged foreign matters, and the like. The invention adopts the following auxiliary substances: purified water, notopterygium root and cherokee rose. The traditional Chinese medicine can treat kidney/bladder channel tissue disease in clinic.